Organon & Co. (NYSE:OGN) Hits New 12-Month High – Should You Buy?

Organon & Co. (NYSE:OGN) shares hit a new 52-week high during mid-day trading on Tuesday . The company traded as high as $13.78 and last traded at $13.7750, with a volume of 4872488 shares trading hands. The stock had previously closed at $13.78.

Analysts Set New Price Targets

Separately, Weiss Ratings lowered shares of Organon & Co. from a “hold (c)” rating to a “hold (c-)” rating in a report on Monday, August 3rd. Five research analysts have rated the stock with a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Reduce” and a consensus price target of $11.40.

Organon & Co. Price Performance

The firm has a fifty day moving average of $13.62 and a two-hundred day moving average of $11.38. The stock has a market capitalization of $3.62 billion, a P/E ratio of 17.89, a P/E/G ratio of 1.28 and a beta of 1.52. The company has a debt-to-equity ratio of 8.43, a current ratio of 1.95 and a quick ratio of 1.44.

Organon & Co. Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, September 10th. Stockholders of record on Friday, August 14th will be paid a dividend of $0.02 per share. The ex-dividend date is Friday, August 14th. This represents a $0.08 dividend on an annualized basis and a dividend yield of 0.6%. Organon & Co.’s dividend payout ratio (DPR) is currently 10.39%.

Institutional Trading of Organon & Co.

A number of hedge funds have recently bought and sold shares of OGN. Private Management Group Inc. grew its stake in Organon & Co. by 38.3% in the fourth quarter. Private Management Group Inc. now owns 4,347,073 shares of the company’s stock valued at $31,169,000 after purchasing an additional 1,204,979 shares during the last quarter. California State Teachers Retirement System boosted its holdings in shares of Organon & Co. by 34.8% in the 1st quarter. California State Teachers Retirement System now owns 327,075 shares of the company’s stock valued at $1,959,000 after buying an additional 84,497 shares in the last quarter. Orographic Financial Advisors LLC purchased a new stake in Organon & Co. during the first quarter valued at approximately $1,522,000. Sei Investments Co. lifted its position in Organon & Co. by 82.0% during the first quarter. Sei Investments Co. now owns 190,057 shares of the company’s stock valued at $1,139,000 after acquiring an additional 85,657 shares during the last quarter. Finally, Brandes Investment Partners LP boosted its stake in Organon & Co. by 46.7% in the fourth quarter. Brandes Investment Partners LP now owns 606,499 shares of the company’s stock valued at $4,349,000 after acquiring an additional 193,064 shares in the last quarter. Hedge funds and other institutional investors own 77.43% of the company’s stock.

Organon & Co. Company Profile

Organon & Co is a global healthcare company that was established as an independent, publicly traded entity following its spin-off from Merck & Co in June 2021. Headquartered in Jersey City, New Jersey, Organon focuses on delivering therapeutic solutions across women’s health, biosimilars, and established brands. The company’s creation reflected a strategic effort to concentrate on specialty pharmaceuticals and legacy products with proven patient impact.

In women’s health, Organon provides a broad portfolio of products addressing reproductive and gynecological conditions, including fertility treatments, contraception, and hormone replacement therapies.